Active ingredientFedratinibCat. No. P-F012-001CAS 936091-26-8Family · Pharmaceutical analytical standards
Fedratinib
An oral JAK2 kinase inhibitor, approved in the United States in August 2019 for adults with intermediate-2 or high-risk primary or secondary myelofibrosis, a bone marrow cancer. This family brings together the active ingredient, labelled standards, nitrosamines and other impurities.
Did you know?At the time of its approval it was hailed as the first new treatment for myelofibrosis in nearly a decade.
Go to the active ingredient →Active ingredientFedratinibCat. No. P-F012-001CAS 936091-26-8
Isotopically labelledFedratinib-d8Cat. No. P-F012-002
NitrosamineN-Nitroso FedratinibCat. No. P-F012-003
ImpurityFedratinib Impurity 1Cat. No. P-F012-004
ImpurityFedratinib Impurity 2Cat. No. P-F012-005
ImpurityFedratinib Impurity 3Cat. No. P-F012-006CAS 936091-39-3No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.